On 11 February 2020, the World Health Organisation (WHO) made an announcement regarding the official name of a new respiratory illness.
Fast forward to near the end of 2020 and COVID-19 had struck populations with unthinkable speed, at an unprecedented scale and with previously unimaginable consequences.
The enforced and dramatic changes in people’s behaviour inevitably impacted the healthcare space. Prior to the pandemic, digital health was an area slowly building momentum, with many sharing Aptar Pharma’s vision of a connected future where technology is increasingly integrated into intelligent patient care. In just a few months, that trend shifted several gears, with early adoption accelerated by the need to continue to provide high-levels of patient care while also limiting person-to-person contact as much as possible.
For pharmaceutical companies looking to embrace this rapidly evolving connected future, success will need to consider many aspects including cost management, regulatory compliance and long-term support for patient health.